Biocon Ltd.

: Building a Biotech Powerhouse

Company Case Analysis EMBA 240 Professor Sanjay Jain

ROBERT PAUL ELLENTUCK EMBA 2011 5/10/2010

COPYRIGHT 2010, 2011 ALL RIGHTS RESERVED ROBERT PAUL ELLENTUCK

THE COPYRIGHT HOLDER EXPRESSLY PROHIBITS ANY AND ALL COPYING, FAXING, SCANNING, XEROXING, REPRODUCING, TRANSMISSION, DISSEMINATION, FORWARDING, PRINTING, SUBMISSION (EITHER ELECTRONICALLY OR OF A SCANNED OR OTHERWISE REPRODUCED COPY, OR OF THE ORIGINAL COPYRIGHTED MATERIAL, A COPY OF THE COPYRIGHTED MATERIAL, OR OF A PORTION OF THE ORIGINAL OR COPIED COPYRIGHTED MATERIAL), OR ANY AND ALL OTHER ACTIONS: ELECTRONIC OR OTHERWISE, OF ANY PORTION OF THIS COPYRIGHTED MATERIAL OR THE ENTIRE COPYRIGHTED MATERIAL, WHICH MAY IN ANY WAY VIOLATE THE RIGHTS OF THE COPYRIGHT HOLDER. SUCH PROHIBITION INCLUDES THE ORIGINAL COPYRIGHTED MATERIAL, A COPY OF THE ORIGINAL COPYRIGHTED MATERIAL, A PORTION OF THE ORIGINAL COPYRIGHTED MATERIAL, A PORTION OF THE COPIED COPYRIGHTED MATERIAL, AN ELECTRONIC VERSION OF THE COPYRIGHTED MATERIAL, OR ANY OTHER POTENTIAL VERSION OF THE COPYRIGHTED MATERIAL (WHETHER THE TECHNOLOGY EXISTS AS OF THE COPYRIGHT DATE, OR IS YET TO BE INVENTED). THIS PROHIBITION EXPLICITLY EXTENDS TO ALL OF THE ABOVE ACTIONS, BUT IS IN NO WAY LIMITED TO THEM. ANY USE OF THE COPYRIGHTED MATERIAL, IN ANY MANNER, CAN ONLY BE WITH THE PRIOR CONSENT AND AUTHORIZATION THAT IS BOTH WRITTEN AND EXECUTED BY THE COPYRIGHT HOLDER AND THE OTHER PARTY, RELATING SPECIFICALLY TO THIS COPYRIGHTED MATERIAL. THIS COPYRIGHT, AND ALL OF THE PROTECTIONS THAT IT AFFORDS THE COPYRIGHT HOLDER EXPLICITLY EXTEND TO ANY COPYRIGHTED MATERIAL, IMAGE, FILE, DATA, OR ANY OTHER ATTACHMENT IN ANY FORM, ELECTRONIC, PRINTED, OR IN ANY OTHER FORMAT, THAT ARE ATTACHED TO THIS COPYRIGHTED MATERIAL IN ANY MANNER OR FORM, AND TO WHICH THE COPYRIGHT HOLDER HOLDS OR IS ELIGIBLE, UNDER THE WIDEST POSSIBLE INTERPRETATION, TO HOLD A COPYRIGHT TO. THE INTERPRETATION OF THE COPYRIGHT HOLDERS RIGHTS SHALL BE AS BROAD AS THE LAW ALLOWS, AND IN NO WAY SHALL BE LIMITED BY THE RIGHT OR RESTRICTION NOT BEING STATED. THE COPYRIGHT SHALL ALSO EXTEND TO ALL FUTURE PROTECTIONS UNDER THE LAW, AS THEY BECOME AVAILABLE. THE FAILURE TO MENTION A PROTECTION OF ANY CURRENT OR FUTURE COPYRIGHT LAW SHALL NOT IN ANY WAY INDICATE THAT THE LAW DOES NOT APPLY IN FULL TO THE COPYRIGHTED MATERIAL. IF ANY PORTION OF THIS DOCUMENT OR COPYRIGHT IS NOT DEEMED TO APPLY, AT ANY TIME, FOR ANY REASON, THAT SHALL IN NO WAY LIMIT ANY AND ALL OTHER PROTECTIONS THAT THE COPYRIGHT GRANTS, NOR SHALL IT LIMIT FUTURE PROTECTIONS FROM APPLYING AS THEY BECOME AVAILABLE. THIS COPYRIGHT IS IN NO WAY INTENDED TO INFRINGE ON THE RIGHTS OF ANY OTHER PARTY.

Why Has Biocon been so successful? Biocon is a fully integrated biopharmaceutical company located in Bangalore, India that is focused on biopharmaceuticals, custom research and clinical research.i They have five subsidiary companies that include Syngene, Clinigene, Biocon Biopharmaceuticals, AxiCorp, and NeoBiocon.ii Biocon, Syngene and Clinigene together employee nearly 3600 biologists, chemists, medical practitioners, engineers, and general administrators.iii Biocon delivers products and solutions to partners and customers in over 50 countries. They are the largest biotechnology company in India. As of 2008, Biocon was ranked as the 7th largest biotech company in the world based on the number of employees. Biocon was founded in 1978 as a joint venture between Biocon Biochemicals Ltd. (BBL) of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw.iv When Mazumdar-Shaw saw BBL being acquired by Unilever plc and ICI Ltd., she held onto her stock and formed Biocon India. Since its inception, Biocon has evolved from an enzyme manufacturing company to a fully integrated biopharmaceutical enterprise.v They have received numerous accolades through the years for such achievements as the first biotechnology company to receive ISO 90001 certification in India, first Indian company to manufacture and export enzymes to the US and Europe, first Indian company to receive US funding for proprietary technologies, and only the second Indian company to cross a market capitalization of $1 billion on the first day of listing. Mazumdar-Shaw, the co-founder of Biocon, remains the chairman and managing director of Biocon. She and her husband John Shaw own over 60 percent of the companys stock. Not only has Mazumdar-Shaw accepted numerous awards through the years for the success of Biocon, she has received numerous awards highlighting her own successes (to include receiving one of Indias highest civilian honors, a lifetime achievement award, business leader of the year in Biotechnology, and Best Entrepreneur). Biocons success began at its inception with Mazumdar-Shaws sequential growth strategy for the company. Each business she added to the company added to the mission of Biocon by providing a stepping stone toward making Biocon a biotechnology powerhouse. These stepping stones included consolidating Biocons core skills in enzymes, establishing a footprint in biopharmaceuticals, and partnering with global firms. Biocons successes in these areas, led Mazumdar-Shaw to pursue an even riskier adventure into the world of drug discovery. The bulk of Biocons revenue in their early years came from their success in generic drug manufacturing. Generic drugs typically cost 20 to 80 percent less to manufacture because the products are not burdened with legacy expenses of research, development, clinical trials and marketing (as the original pharmaceutical products would be). Biocon, like many other drug companies, used a large portion of their generic revenue to finance their breakthrough into drug discovery. However, increased competition in the biopharmaceutical market, led Biocon to the realization that their success in generics alone, would not allow them to reach their global
3

aspirations. Additionally, changes in the regulatory environment prohibited them from manufacturing and marketing generic versions of patented drugs (one of the main ways Indian companies were prospering). For nearly two decades, Biocon expanded and diversified into various fields beyond its specialization in enzymes. These fields included biopharmaceuticals, custom research, and clinical research. In 2004, their success led them to issue an initial public offering (IPO), valuing the company at $1.1 billion. In 2005, they earned revenue of US $167 million. The importance of Biocons manufacturing of enzymes was the basis for their competitive advantage of fermentation. Biocons fermenting capacity gave it the ability to scale up an industrial process and the platform to pursue discovery-led growth. Biocon was able to differentiate itself from competitors in the making of Active Pharmaceutical Ingredients (APIs) by deploying their core skills in fermentation while the global market for statins (a class of drug used to lower plasma cholesterol level) was shrinking in value as statins lost patent protection, though the market was growing in volume. Biocon was also successful because they went beyond making APIs to supplying formulations to innovator companies. Biocons ability to maintain molecular biology as their core competence has been one of the most instrumental reasons for their success. Most companies come into the drug discovery world only having skills in synthetic chemistry. Biocon is equally involved in synthetic chemistry and molecular biology. Biocon also demonstrated sophisticated business practices by allowing their clinical trials to be handled by their subsidiary, Clinigene. This subsidiary leveraged Indias large population and low cost medical and scientific professionals to provide clinical research services at low prices and to facilitate rapid establishment of trial groups. By the year 2008, it was estimated that 30 percent of global clinical trials would take place outside of the US and that Europe and India would be their preferred destination (due to speed of patient enrollments and shorter timelines). Additionally, the clinical trial market was estimated to grow by 20 percent each year, which would likely benefit Biocon even more. As Mazumdar-Shaw began to envision her goal to generate a six-fold increase in revenue within the next decade by building a strong discovery orientation biotechnology enterprise, it was apparent that Biocon was already leading the way in several areas. In the research stage of drug discovery Biocon had already launched a biodiversity program to collect, catalogue and conserve rare and diverse species of indigenous bacteria, yeast, and fungi. This was a valuable tool in discovering new biotech products. In the development phase of drug discovery, Biocon relied on its partnerships with global biotech firms to share development costs, which wasa powerful tool that helped to de-risk Biocons own investments. Biocon appears to be achieving its success through many channels. Their intellectual asset creation, state-of-the-art manufacturing capabilities, international benchmarks for the
4

quality of their regulatory systems and their disease-specific clinical research have all been invaluable.vi They follow precise manufacturing, laboratory and documentation practices that ensure consistent high quality results. With Mazumdar-Shaw as their leader they develop cross functional teams to encourage empowerment, communicates clearly and truthfully to help shape organizational values, and consistently pursues biotechnology commercialization opportunities that are exciting but very risky.vii Explore arguments in favor of success in the future. Based on Biocons success record to date and the powerful leadership of MazumdarShaw, there are many areas we can examine in favor of success for the future of this company. To begin, their sequential growth strategy since inception has proved to be priceless in their aspirations to become a biotechnology powerhouse. Their consolidated core skills in enzymes, established footprint in biopharmaceuticals and partnerships with global firms is leading to a far more rewarding realm for them in drug discovery. By partnering with global companies they can manage their risk better and lower costs in drug discovery. Drugs based on biology are also estimated to replace 70 percent of conventional therapies by 2025,which is another one of Biocons competitive advantages. Biocon has a good source of revenue to move into drug discovery since they are a major manufacturer of generics. They are one of 74 manufacturing facilities in India certified by the US Food and Drug Administration (FDA) that sold generics in both the US and Europe. In 2006, there were $82 billion in global blockbuster drugs facing patent expiry,which would mean the generic market would only grow. Indias share of global generic market was expected to increase to about 33 percent in 2007, from 4 percent in 2004. Major drug companies were also interested in driving down costs, so they were looking for partner specialist firms in India and China as sources of input for research and clinical development. viii By focusing on unique technology and patents in the US, Biocon has been given exclusive global rights for many products. Another argument for success revolves around Biocons focus on diversification in their early years. Their manufacturing of enzymes was 15 percent of their revenue and was expected to grow 6.5 percent a year. Enzymes were a springboard for fermentation, which was a core skill in later stages of the value chain of biopharmaceuticals. Biopharmaceuticals represented 80% of Biocons turnover and the global generics market was set to grow even more as dozens of drugs came off patent. Governments, insurers and health care organizations were turning to generics to reduce costs. Additionally, more of the global drug companies were exporting parts of the value chain to low cost producers like India. Biocon was also manufacturing via fermentation. This was important because molecular biology produces a product that is less likely to fail in the end product. As a biologic process, molecular

biology is less intrusive when embedded in a biological system than a synthetic drug, and less likely to fail in a clinical trial. Biocon was successful in forming Syngene to capture the business of research process outsourcing (RPO). This type of outsourcing was being done by many global drug companies who wanted to reduce their R&D costs and shorten product valuation times. Biocon positioned itself to provide synthetic chemistry in partnership with established pharmaceutical companies and molecular biology in partnership with biotechnology companies while many of their competitors had a specialty focus. To be successful in the future in drug discovery, Biocon needed to excel in three areas of drug discovery: research, development and commercialization. In research, Syngene and Clinigene were leading the way for Biocon by providing a solid platform to move into drug discovery. Biocon has had an in-house R & D team and a biodiversity program that was helping in the discovery of new biotech products. Biocons partnerships with biotech startups were also seen as a key element as they further helped Biocon to integrate backward into discovery research. Building on capabilities in clinical trials, Biocon had already taken tentative steps toward involvement in the development state of drug discovery. They limited their activities to known targets and known molecules and relied on partnerships with global biotech companies to share development costs. Partnering with India was seen as a fast track way to climb the valuation chain by many foreign companies. Through partnering, Biocon takes on molecules for development that were built by partners who invested in the drug research and moves the drug development process forward. They save on the costs on research while their foreign partners save on drug development. The last stage of drug discovery is commercialization, which is where Biocon has the least expertise and they were making investments to create the manufacturing capacity for industrial scale-up to meet commercial demand. Biocon would also need to comply with manufacturing standards and deploy a sales force with expertise in marketing and promotions. Through fine tuning of their commercialization skills and strengthening of some of their core capabilities, Mazumdar-Shaws vision to turn Biocon into a top-10 biotechnology firm with sales exceeding $1 billion by 2015 appears to be an achievable goal based on the success and performance of this company to date. Explore reasons for concern. The primary reason of concern for Biocons success is the riskiness associated with drug discovery. Only 1 in 5,000 molecules reach the clinical trial stage, only 1 in 500 undergoing clinical trials reach the commercial stage. Biocon has 9 molecules at various stages of
6

development. The odds are against Mazumdar-Shaws expectations that all 9 molecules will reach commercialization by the end of the decade. Additionally, the low availability of venture capital in India requires Biocon to fund/take on a large portion of the risk. Drug discovery in the words of Mazumdar-Shaw is managing infinite risk, that was not in the mindset at Biocon but had to be learned. Drug discovery is different from Biocons traditional revenue source, of generic drugs, which do not involve a unique discovery but differ only in price. Drug discovery also doesnt provide the instant cash gratification that generics provide. The regulatory environment that had made generics so attractive, and was a critical part of Biocons income was another reason for concern. India had introduced a full-fledged patent regime in compliance with the World Trade Organization (WTO) agreement on Intellectual Property. Previously Indian companies that had been able to manufacture generic versions of drugs patented in other countries would no longer be able to do so. This would severely impact these companies, including Biocon, as it would cut their income of manufacturing and marketing of patented drugs and limit their funds for drug discovery. Generics would no longer be allowed until the patent expired. This circumstance was creating an impetus to change their business model and integrate it with their evolving strategy around drug discovery moving forward. Another reason for concern was whether or not Biocons four broad areas of specialization: enzymes, biopharmaceuticals, custom research and clinical research would distract it from moving into drug discovery. Enzymes provided a springboard for Biocons competitive advantage, offering leverage in stage three of the value chain of pharmaceuticals. However, Biocon had less than a one percent share of world market in enzymes, and was up against two large European players with 70 percent of the market share. Biocon competes directly against niche players such as many Chinese firms are. The low cost Chinese firms could potentially drive Biocon out of the sector on price. In addition, the European players may push Biocon out of the market if they increased market share. Biocon makes 45 percent of their revenue from ingredients (APIs) for statins. Although Mazumdar-Shaw is confident that as the brand name statins lose patents the market for Biocons ingredients will shrink in value but the volume of product sold will increase. However, there is no guarantee that Biocon will gain any of this increased volume. In addition, if other competitors move in with lower priced APIs and take away Biocons volume the resulting reduction in cash flow will present a major problem for their plans to expand into drug discovery. There is also reason for concern with two of Biocons subsidiaries in relationship to drug discovery research in the first stage of drug discovery. Clinigene makes up an extremely small part of the rapidly growing clinical trial business, and has yet to build up its capabilities as a clinical research organization. Syngene is operating in a competitive space against everyone from full-service global drug development companies to teaching hospitals. While a growing
7

area, the extent of competition could prove formidable to Biocon as they change their focus to drug development and away from their core businesses. Biocon is also outsourcing some of the stages associated with drug discovery research because they dont have the skills in this area. This may prevent them from developing the skills that are crucial to drug discovery. With regards to drug discovery development, Biocon is only taking tentative steps in this stage by building on its capabilities in clinical trials, which are very limited based on revenue. The company has limited its activities to known targets and known molecules and is also relying on partnerships with global biotech companies to share development costs. Its current activities utilized existing antibodies and molecules created by the firms partners, instead of demonstrating the ability for Biocon to develop their own new drugs, which is its stated goal. Biocon has very little experience in commercialization, the final stage of drug discovery and development. While the firm was investing in manufacturing capacity, the critical areas of deployment of a sales force and development of expertise in promotions aimed at physicians and end-customers are being neglected. This leads us to wonder if there is validity in discovering and developing a drug if theyre not ready to sell it. This is especially true in a lucrative market such as the US, which is heavily dependent on marketing. Biocon may be spreading its resources too thin as it moves into drug discovery and faces increased competition in generics, APIs for statins, and the substantially higher costs in drug discovery. Moving away from their traditional area of commodities and business to drug discovery and development also requires developing several new competencies such as building a drug pipeline, project management, regulatory compliance, manufacturing and marketing. These will all place great financial strain on the companys resources. Mazumdar-Shaw needs to determine if its worth it to take financial risk to expand her vision of achieving annual revenues of $1 billion. The final reason of concern for Biocons future success relates to the implementation of the WTO patent law (combined with a repeal of restrictions on foreign investments under WTO). This means that multinational corporations will begin invading the Indian market in force and give Biocon more competition. Not only will they be competing in the local market against local players, but they will also be competing in the local market against Merck and Bristol-Meyers Squibb. In addition, multinational generic manufactures, such as Teva Pharmaceutical Industries, will be competing against Biocon in its home market. The approximately 10,000 small companies in Indias domestic market currently producing copycat patents for local use will all be competing for the generic market or attempting drug development to avoid going out of business.ix Based on the prospective competition it may not be the proper time for Biocon to expand their business to drug development.

Assume the role of Mazumdar-Shaw's top management team and develop an action plan that will enable the company to meet its aggressive goals. Be as specific as possible in developing your action plan. In assuming the role of Mazumdar-Shaws top management team to develop an action plan that will enable Biocon to meet its aggressive goal we first composed the goal into a single, coherent and quantifiable statement, which is noted below. We then split the statement into component parts that could be reasonably managed within the corporate skills of Biocon. The intent of this approach was to break-up the effort so that risks could be more carefully managed and rewards or consequences could be more closely measured. As identified by Michael Porters framework in The Competitive Advantage of Nations,x Biocons corporate strategy provides leverage internally and externally to establish a competitive advantage in achieving the goal. Biocon Ltd goal for 2015: Biocon Ltds goal is to become a top-10 biotechnology firm by reaching annual sales of $1 billion by 2015. As of March 2005, Biocon was positioned at number 14 in global rankings based on sales according to exhibit one in the case.xi As of July 2008, they were positioned at number 20 in the global rankings based on sales.xii Despite a slip in overall ranking, Biocon has successfully grown their drug discovery revenue as planned. However, in comparison to other global competitors, they have moved down in relative ranking. Biocons overall success was made evident by a press release on September 24, 2009, when Biocon announced that they were marked as one of only 20 Indian companies on Forbes Best under a Billion List selected from over 12,000 publicly-listed firms with sales of less than $1 billion in the Asia-Pacific region. Only 20 Indian companies have been featured in the list this year, which is dominated by companies from China. All other companies have both increased sales and profits over the past 12 months or are forecasted to do so in upcoming quarters. Apparel, media, technology and health care led the way, said Forbes. This year's list is dominated by companies that have withstood challenges that threatened their survival and those that have demonstrated exemplary entrepreneurship.xiii It is also worth noting a recent revenue statement made by MazumdarShaw herself that All segments of our businesses have demonstrated robust growth. Mazumdar-Shaw said the company was confident of sustaining the growth momentum by using its differentiated profile through its global partnerships. She said the partnerships would enable the company to reach out to lucrative opportunities in emerging and developed markets. xiv Observations of Biocon make it evident that the company is focused on accomplishing its goal. In the book, The Indian Way, the authors state that Mazumdar-Shaw had built risktaking into her companys culture through her own modelingconsistently pursuing biotechnology commercialization opportunities that looked exciting but also very risky.xv This focus is also evident by comments from Mazumdar-Shaw in an interview of over 100 Indian Executives where she states, "We have transformed ourselves into an integrated biopharmaceutical business. Our key areas of focus are diabetes and oncology. We are developing
9

oral insulin and antibodies for specific cancers."xvi The figure below is a graph of Biocons Discovery Pipeline. It also offers a visual of the diverse segmentation balance between generics and discovery drugs as well as the focus areas noted by Mazumdar-Shaw.xvii

The action plan below is proposed as a means to achieving the goal of reaching annual sales of $1billion by 2015, and depending on the relative rankings of other firms in the sector [NAICS 325412, SIC 2834,5] to become a top-10 global biotechnology firm. Acting as Mazumdar-Shaws management team for Biocon, we identified two major steps to accomplish the goal with sub-activities and two major barriers to overcome as part the action plan. These are outlined below. Steps to accomplish: 1) Build a highly effective project management team to accomplish step two below; comply with regulations; control manufacturing; and create the marketing necessary for achieving the sales goal. 2) Build a portfolio of strong candidate drugs to mature as efficiently as possible according to a market driven schedule of at least one-per year for the next five years, 2010-2015. a) Research: Under our research efforts, we will screen molecules and genes with the highest probability of success and lowest consequence of failure by managing risks on the most likely candidates that will increase revenue on pharmaceuticals in excess ($600
10

million by 2015) of the expected decrease in revenue on generics ($19 million starting in 2008). b) Development: We will leverage the outputs from research by creating hybrid cells and scaling them up with enzymes to establish a platform for commercialization. c) Commercialization: Our success will depend on receiving regulatory approvals and tactically marketing our products to reach our sales goal. Barriers to overcome: 1) As we shift our business model from generics, to also include drug discovery, we must determine how much to press the risk-reward continuum on all of our financial priorities by seeking a balance between our capital obligations with venture capitalists, our subsidiaries, our partners and our existing generics segment. We must also carefully monitor our new products for potential post-market liability consequences and identify potential opportunities for product growth events in the marketplace such as expanding into new markets or increasing our share of existing markets. 2) In conjunction with overcoming the above barrier, we must design and build quality into all of our new or expanding processes. By leveraging our recent capital expenditures of $135 million ($100 million in 2005-06 for enzyme fermenting and $35 million in 2008 to increase biopharmaceutical capacity), we must also increase our existing productivity through continuous improvement targets on our legacy processes so that they will approach our new process capacities. This will enable us to more effectively integrate our total productive output by supporting operations in all segments to exceed the expected decline in generic revenues with the expected increase in biopharmaceutical revenues. The action plan detailed above provides a strong internal framework to accomplish our goal of $1 billion in annual sales by 2015. Exhibit 1 provides an excerpt of the framework in a more detailed view that can be revised as needed based on quarterly reviews during execution of the action planxviii. The global business climate will be a major determinant of whether or not we will achieve the ranking of a top-10 biotechnology firm. As Mazumdar-Shaws top management team, we will need to assist in controlling corporate matters on operational and tactical timeframes and advise on corporate matters from a strategic time-frame perspective. In reviewing the framework offered by Porter, we learned that we need to integrate our action plan for Biocon with a strategic plan that addresses factor conditions, demand conditions, related and supported industries, firm strategies, structure and rivalry. In some aspects, Biocon has taken an approach that addresses these areas by acquiring subsidiaries with Syngene in the research segment and Clinigene in the development segment. Biocon has also taken this approach by setting up a controlling interest in partnerships with CIMAB in development and AxiCorp in commercialization (through distribution), among other minority stake interests. These relationships are strategic business moves that seek to address the factor and demand conditions as well as the related and supported industries. The remaining areas that Biocon should seek to
11

strengthen are the strategies that encompass their local and global approach to rivalries and government policies. Biocons strategy for establishing its global position could be compared with a description offered by Pankaj Gemawat in a December 2005 Harvard Business Review article, titled Regional Strategies for Global Leadership. In this article, Gemawat writes Leading-edge companies are starting to grapple with these definitional issues [on varying what defines a region]. For example, firms in sectors as diverse as construction materials, forest products, telecommunications equipment, and pharmaceuticals have invested significantly in modern mapping technology, using such innovations as enhanced clustering techniques, better measures for analyzing networks, and expanded data on bilateral, multilateral, and unilateral country attributes to visualize new definitions of regions.xix Biocon persists as Indias largest and most successful biotechnology firm by a healthy margin over its other national competitors. From a local strategy perspective, they are comfortably positioned to stay ahead of their in-country rivalries. For Biocon to reach its desired position in global ranking within the top-10, they must baseline their goals on the performance characteristics of at least the annual number 10 performer each year. As of 2005, Millenium Pharmaceuticals (USA) was the number 10 ranked company. As of 2010, Actelion was the number 10 ranked companyxx. Comparing financially reported sales for 2009 between Biocon Ltd and Actelion in US dollars, the difference is roughly twice for Actelion at approximately $1.7 billion than for Biocon at approximately $350 million (based on an exchange rate of 1 INR = 0.0219539 USD retrieved on May 7, 2010). This difference shows that Biocon has a very aggressive goal of reaching at least the number 10 global rank by year-end sales figures for 2009. Holding all other variables constant, at this rate it would require Biocon to achieve an annual average increase in sales on the order of $88 million per year for the next four years to reach $1 billion in sales by 2015. The action plan proposed is a strong plan that needs to be integrated comprehensively with the strategic plan so that the goal is more achievable in the given time frame and considers the relative factors of local, region, demand, support industry, competition, risk and post-market consequences.
i

Biocon General Information, retrieved on May 8, 2010 on-line at Biocons website, http://www.biocon.com/biocon_aboutus_factsheet.asp Biocon General Information, retrieved on May 8, 2010 on-line at Biocons website, http://www.biocon.com/biocon_aboutus_factsheet.asp iii Biocon General Information, retrieved on May 8, 2010 on-line at Biocons website, http://www.biocon.com/biocon_aboutus_factsheet.asp iv Anonymous. (2007, July 21). Biocon India. Retrieved May 8, 2010 from http://www.iloveindia.com/economy-of-india/top-50companies/biocon.html v Anonymous. (2007, July 21). Biocon India. Retrieved May 8, 2010 from http://www.iloveindia.com/economy-of-india/top-50companies/biocon.html
ii

vi
vii

Anonymous. (2004). Naukri Hub. Retrieved May 8, 2010 from http://www.naukrihub.com/india/pharmaceutical/top-companies/biocon.html Capelli, P., Singh, H., Singh, J., and Useem, M., The India Way. Harvard Business Press, 2010. viii Richard Balaban, Beyond the Blockbuster, a research report prepared by Mercer Management Consulting, www. Amanet.org/PharmaFocus/food_company/mar_04.htm, referenced May 3, 2010. ix Manjeet Kripalani, India: Bigger Pharma, BusinessWeek online, April 18, 2005, www.businessweek.com/magazine/content/05_16/b3929068.htm, referenced May 3, 2010. x Enright, M., The Geography of Competition and Strategy, Harvard Business School 90793-135, Rev. December 1, 1994, page 4 xi Chandrasekhar, R. (2006). BIOCON LTD: BUILDING A BIOTECH POWERHOUSE, Richard Ivey School of Business, University of Western Ontario 906M70, ver. (A) September 13, 2006, page 9.

12

xii

Anonymous. (2008, July 18). Business Line: CORPORATE: Biocon gets global ranking of 20. Business Line (India) 1.pag. Retrieved May 7, 2010, from NewsBank on-line database (Access World News) xiii Anonymous. (2009, September 24). Biocon among 20 Indian companies in Forbes 'Best Under A Billion' List. Accord Fintech (Mumbai, India) 1.pag. Retrieved May 7, 2010, from NewsBank on-line database (Access World News) xiv Anonymous. (2010, April 29). Biocon profit zooms to Rs. 293 crore. The Hindu. 1.pag. Retrieved May 7, 2010, from www.Google.com on-line news search xv Cappelli, P., Singh H., Singh, J. Useem, M., The India Way, Harvard Business Press, 2010, page 126 xvi Anonymous. (2007, January 11). India Knowledge @ Wharton. 1.pag. Retrieved May 6, 2010, from link in Appendix B of The India Way, page 276 xvii Biocon Ltd, Discovery Pipeline Graph, retrieved on May 6, 2010 on-line at Biocons website under the R7D menu, http://www.biocon.com/biocon_research_pipeline.asp xviii Van Houten, L. Miyasaka, J. Agullard, K. Zimmerman, J. (WestEd 2006). Adapted from excerpt in Developing and Effective School Plan: An Activity-Based Guide to Understanding Your School and Improving Student Outcomes. Handout 4.7-2. xix Ghemawat, P., Regional Strategies for Global Leadership, Harvard Business Review, December 2005, page 10 xx Research and Markets Offers Report: Top 10 Biotech Companies: Media Monitor. (2010, February). Wireless News, 1. Retrieved May 7, 2010, from ABI/INFORM Complete. (Document ID: 1972670581).

13